

AVACEN Medical Issued U.S. Patent for CATHSTA™ Large-Bore Catheter Stabilization Device

Innovative angle-adaptive mechanical stabilization for large-bore catheter access

CARLSBAD, CA, UNITED STATES,


December 31, 2025 /

EINPresswire.com/ -- [AVACEN](#), Inc., a leader in non-invasive and access-adjacent medical device innovation, today announced the issuance of a U.S. utility patent for its CATHeter STAbilization (CATHSTA™) device.

CATHSTA™ is designed for high-acuity applications requiring secure large-bore vascular access, including transcatheter cardiac interventions, mechanical circulatory support, indwelling, extracorporeal membrane oxygenation (ECMO), and renal replacement therapies.

The CATHSTA™ system provides angle-adaptive mechanical stabilization for large-bore arterial access, helping reduce catheter migration and access-site stress during complex and prolonged procedures. The technology is protected by U.S. Patent No. 12,447,315.

From a commercial perspective, CATHSTA™ combines a low-COGS, high-margin disposable model with a workflow-neutral design, enabling adoption without procedural disruption or capital investment. The product is intended to scale efficiently through existing global hospital procedural sales channels.



"We are selectively initiating strategic discussions around potential acquisition, licensing, or manufacturing and distribution partnerships for CATHSTA™," said Thomas [Muehlbauer](#), CEO of AVACEN. "CATHSTA™ addresses a rapidly expanding market with an expected CAGR approaching 10%, which materially enhances the long-term strategic value of the issued patent."



About AVACEN, Inc.

AVACEN (Advanced Vascular Circulation ENhancement) develops and markets innovative, non-invasive medical devices designed to enhance microcirculation and support procedural precision. Based in Carlsbad, California, AVACEN is committed to improving patient outcomes through scientifically supported, patent-protected technologies.

Thomas G Muehlbauer

AVACEN, INC.

[email us here](#)

Visit us on social media:

[LinkedIn](#)

[Instagram](#)

[Facebook](#)

[YouTube](#)

[X](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/879348414>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.